Skip to main content
[Preprint]. 2023 Mar 20:2023.02.24.529926. Originally published 2023 Feb 24. [Version 2] doi: 10.1101/2023.02.24.529926

Figure 2. Functional validation of lung integrin-binding and MMP-degradable peptides.

Figure 2.

a) Cell area fold change 2 hours after seeding human lung fibroblasts (HLFs) onto glass coverslips functionalized with intergrin-binding peptides relative to a negative control (glass coverslip treated with silane but no peptides). b) Cell area fold change for lung tropic MDA-MB-231 breast cancer cells in comparison to negative control. c) Cell area fold change on a subset of the integrin-binding peptides in the presence of cilengitide, reported in comparison to positive control (no cilengitide). d) Fold change in gene expression, measured via qRT-PCR, for αv, β3 and β1 integrins in lung tropic MDA-MB-231 breast cancer cells and HLFs, each gene is normalized to the parental MDA-MB-231 breast cancer cells. e) Illustration of HLFs in 3D hydrogels and measurement of cell protrusions quantification. f) Representive images of HLFs after 6 days of encapsulation. g) Quantification of HLF populations with different number of protrusions for individual MMP degradable peptides and lung MMP degradable peptide cocktail. h) HLF protrusion length for individual MMP degradable peptides and lung MMP degradable peptide cocktail. All data are mean + s.d. Statistical analyses were performed using Prism (GraphPad). Data in (a), (b), (c), (d), (g) and (h) were analyzed using a one-way analysis of variance followed by a Dunnett’s multiple comparison test with 95% confidence interval. *, **, ***, and **** indicate P < 0.05, P < 0.01, P < 0.001, and P < 0.0001.